Skip to main
VSTM
VSTM logo

Verastem (VSTM) Stock Forecast & Price Target

Verastem (VSTM) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 59%
Buy 35%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

Verastem Inc. is advancing its late-stage development of novel anticancer agents, with promising data from the FRAME and RAMP 201 trials indicating improved efficacy and safety in cancer treatments, particularly for KRAS mutant low-grade serous ovarian cancer (LGSOC) and non-small cell lung cancer (NSCLC). The company anticipates significant revenue potential, estimating over $400 million in global sales for LGSOC and $200 million for NSCLC starting as early as mid-2025, contributing to a strengthened outlook following recent management discussions. Positive changes in operational focus, strong near-term visibility, and potential competitive positioning in the G12D inhibitor market further support the optimism surrounding Verastem's future performance.

Bears say

Verastem Inc's stock faces significant downside risks primarily due to the lack of substantial and definitive randomized data for its lead asset, avutometinib, which raises concerns about its efficacy and safety in clinical trials. Additionally, competitive pressures may adversely impact patient enrollment and market uptake, while the targeted nature of their treatments could restrict the initial market opportunity due to a limited addressable population. Furthermore, if the clinical development program fails to progress adequately, shares could potentially revert to a valuation aligned with the company's net cash position, indicating a bleak financial outlook for investors.

Verastem (VSTM) has been analyzed by 17 analysts, with a consensus rating of Buy. 59% of analysts recommend a Strong Buy, 35% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Verastem (VSTM) Forecast

Analysts have given Verastem (VSTM) a Buy based on their latest research and market trends.

According to 17 analysts, Verastem (VSTM) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Verastem (VSTM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.